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IN this study it is reported that: (1) the levels of blood
platelet-activating factor and serum tumour necrosis fac-
tor significantly increased after coronary ligation and
reperfusion, compared with sham-ligated controls, in an
anaesthetized rat model; (2) compared with vehicle con-
trols, pretreatment with the PAF antagonist BN 50739
(10 mg/kg, i.v.) produced significant decreases in infarct
size (from 29.6 + 4.0% to 22.4 + 2.1%, p < 0.05 after 3 h
ligation, and from 28.5 + 9.5% to 10.5 + 4.5%, p < 0.01
after 4 h reperfusion) and the level of serum TNF (from
10.4 + 7.7 U/ml to 3.9 + 4.8 U/ml, p < 0.05); and (3) a sig-
nifican positive correlation was found between the level
of blood PAF or serum TNF and infarct size. The present
results indicate that PAF and TNF may be important
mediators involved in myocardial ischaemia and
reperfusion injury, and that PAF antagonists may exert a
protective effect on ischaemic or reperfused myocardium
by inhibiting the interaction of PAF and TNF.
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Introduction
Evidence has recently been accumulated that
platelet-activating factor (PAF) may contribute to
myocardial ischaemia and reperfusion injury. It has
been found that the myocardial infarct size, the
incidence of arrhythmias and the mortality increase
after exogenous administration of PAF to animals,
and that the level of serum tumour necrosis factor
(TNF) markedly increases in patients with acute
myocardial infarction. However, the implication of
increasing level ofTNF and the relationship between
PAF and TNF in myocardial ischaemia and
reperfusion injury remain unclear. In order to explore
the possible role of, and interaction between, PAF
and TNF in myocardial ischaemia and reperfusion
injury, the authors investigated: (1) the changes in
blood PAF and serum TNF during myocardial
ischaemia and reperfusion; (2) the correlation of PAF
or TNF with myocardial infarct size; and (3) the
possible protective effect of PAF antagonist BN
50739, in an anaesthetized open-chest coronary
ligated and reperfused rat model.
Materials and Methods
Animals: Sprague-Dawley male rats, weighing be-
tween 260 and 330 g, were obtained from SIPPR-BK
Experimental Animal Cooperation (Shanghai, China).
The rats were housed in the School of Pharmacy
Animal Resources Center (Second Military Medical
University) at 20 to 22C and fed on standard rat
chow._and tap water ad libitum.
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Reagents: Synthetic PAF, dimethylsulphoxide
(DMSO) and 2,3,5-triphenyltetrazolium chloride
(TTC) were obtained from Sigma Chemical Co. (St
Louis, USA). BN 50739, a recently developed long-
acting PAF receptor antagonist, was kindly provided
by Dr P. Braquet (Institut Henri Beaufour, Paris,
France).
Surgical procedures and experimental design: The
surgical technique described by Curtis was used for
coronary artery ligation and reperfusion with slight
modifications. The rats were anaesthetized with
amobarbital sodium at a dose of 45mg/kg
intraperitoneally, and then tracheotomized and vent-
ilated (tidal volume, 1.5 to 2.0 ml; respiratory fre-
quency, 70 per min) by using a Small Animal Respi-
rator (Jiang-Wan Type 1, Second Military Medical
University, Shanghai, China). A polyethylene cath-
eter was introduced into the right carotid artery for
measurement of blood pressure and for withdrawing
blood samples. Another catheter was introduced into
the left femoral vein for drug infusion. Standard lead
of the electrocardiogram was recorded on an oscil-
lographic recorder (Nihon Kohden, Tokyo, Japan).
A thoracotomy was performed at the level of the
fourth intercostal space. The pericardium was incised
and the left main coronary artery was secured by a
5-0 silk suture around the artery approximately 2 mm
from its origin. After completing the above surgical
procedures, the rats were allowed to stabilize for
15 min. In this period, the rats that had arrhythmias
or systolic pressure lower than 70 mmHg over 5 min
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were excluded from the experiment. The rats
were then randomly divided into eight groups
of which the details are summarized in Table 1.
For Group 2, BN 50739, dissolved in DMSO and
then diluted carefully during continuous stirring
with normal saline, was injected intravenously
5 min prior to coronary ligation. Rats in Group 3
served as vehicle controls which accepted the
same amount of DMSO and normal saline as Group
2. One min prior to reperfusion, BN 50739
was injected intravenously for Group 7, and the
same amount of vehicle as Group 7 was injected for
Group 8.
Determination of myocardial infarct size: The
method described by Montrucchio was used with
slight modifications. At the end of the experiment,
the heart was removed and immediately placed in
10% potassium chloride solution to induce rapid
asystole. After the atria and blood vessels had been
excised, the heart was cut into four sections from
base to apex, each approximately 2 mm thick. The
sections were then washed with cold saline and
stained with freshly prepared 1% TTC in 0.2 M phos-
phate buffer (pH 7.4) at 37C for 15 min. They were
then washed in water, weighed and placed in 40%
formalin solution for fixation. The sections were
photographed using a Nikon F4 camera (Tokyo,
Japan) within 1 week, and their photographs were
used to measure the areas of infarcted myocardium
with a computerized image analysis system (Automa-
tion Institute of China, Peking) according to the
weight of each section.
Determination of blood PAF.. The method for the
extraction, purification and measurement of PAF in
whole blood was used. A blood sample (1.5 ml)
drawn from the carotid artery at the end of experi-
ment was immediately placed into 4 ml of methanol
at 4C for 2 h. The precipitated proteins were re-
moved by vortex shaking for 30 s and then centrifu-
gation for 10 min at 3 000 rpm, and 1.5 ml each of
chloroform and water were added to the supernatant
to effect phase separation. After a second vortex
shaking and centrifugation, the lower, chloroform
phase was dried completely under nitrogen and kept
at-40C until measurement. In all samples, PAF
was purified by thin layer chromatography
(chloroform:methanol:water, 65:35:6, v/v). Syn-
thetic PAF was used as a standard and the treated
samples were subjected to a biological measurement
of PAF by aggregation of washed rabbit platelets.
Assay ofserum TNF: Blood samples (1 ml) collected
at the end of the experiment were kept at 4C for 2 h
and then centrifuged at 3 000 rpm for 15 min. Serum
was then separated and kept at-40C until assayed.
The activity of serum TNF was measured by its
cytotoxic activity on murin L-929 cells in the presence
of actinomycin D. Briefly, L-929 cells were seeded at
a density of 5 x 10 cells per well in 96-well plastic
tissue culture plates (Nunclon Co., Denmark). The
plates were incubated with 5% carbon dioxide at
37C in an incubator (Heraeus Co., Hanau 1, Ger-
many) for 12 h to produce a single cell line. One
hundred btl of the 1-fold diluted serum to be assayed
with actinomycin D (1 ng/ml of the final concentra-
tion) were added to the plates, and then incubated
for 18 h. After the supernatant was removed the cells
were stained with 0.5% crystal violet for 20 min, the
plates were rinsed and dried. The absorbance of the
extract was measured at 570 nm using an enzyme-
linked immunoassay autoreader (DG-3022, East
China Electron-Tube Factory, Xian). A concentration
of I U/ml ofTNF represents the reciprocal of the TNF
dilution which causes 50% cytotoxicity under the
assay conditions.
Statistical analysis: Data are presented as the
mean_+ 1 S.D. Intergroup comparisons for the
myocardial infarct size and the levels of PAF and TNF
were assessed, as appropriate, by a two-tailed analy-
sis of variance or Student’s t-test. A Fisher’s analysis
was used to assess the difference of percentage of
animals with detectable PAF and TNF. A linear cor-
relation analysis was used to assess the relationship
between the infarct size and the level of PAF and
TNF.
Table 1. Experimental groups of rats subjected to coronary artery ligation and
repeffusion
Group n Procedure Treatment Measurement
9 3 h sham-ligation None PAF and TNF
2 9 3 h ligation BN 50739 10 mg/kg IS, TNF and pAF
3 10 3 h ligation Vehicle IS, TNF and PAF
4 11 4 h ligation Vehicle PAF and TNF
5 10 2 h ligation Vehicle PAF and TNF
6 10 / lhligation Vehicle PAFandTNF
7 9 //40
min ligation BN 50739 10 mg/kg IS, TNF and PAF
followed by 4 h
8 10 reperfusion Vehicle IS, TNF and PAF
IS infarct size.
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Table 2. Changes of blood PAF and TNF
Sham-ligated Coronary artery
group
ligated group Reperfused group
lh 2h 3h 4h 4h
PAF 36 + 59 348 + 112 689 + 199 625 + 183 571 + 201 1421 + 454
(pg/ml) (593 + 102) (1399 + 219)
TNF 1.5 + 1.6 4.2 + 2.5" 4.4 + 2.1 10.4 + 7.7 8.3 + 4.1 16.2 + 5.7
(U/ml) (3.9 + 4.8) (6.6 + 4.1)
n 9 for all the groups. The data in brackets were obtained from groups treated with BN 50739, the rest from
vehicle controls, ap < 0.05, p < 0.01, sham-ligated compared with ligated and reperfused vehicle controls.
cp < 0.05, p < 0.01, BN 50739 pretreated compared with vehicle controls.
Results
The changes of blood PAF and serum TNF.. The
changes of blood PAF and serum TNF are summa-
rized in Table 2. In vehicle controls, the level of
blood PAF significantly increased after lh
myocardial ischaemia, reached its peak level which
was 19 times that of sham-ligated controls after 2 h
myocardial ischaemia, and slightly decreased after 3
and 4 h ischaemia but still remained significantly
higher compared with sham-ligated controls. The
level of blood PAF after 4 h reperfusion increased
further compared with those of ischaemic groups,
which was about 40 times that of sham-ligated con-
trois. The level of blood PAF in groups pretreated
with BN 50739 before ischaemia and reperfusion was
not significantly changed compared with vehicle
controls subjected to ischaemia and reperfusion for
the same time period. A minimal amount of PAF was
detected in the blood obtained from three of nine
rats (33.3%) in the sham-ligated group. PAF was
detected in all animals that underwent coronary
artery ligation or reperfusion. The differences in the
percentage of animals with detectable blood PAF in
sham-ligated and the coronary ligated or reperfused
groups were significant (p< 0.01).
In the vehicle controls, the level of serum TNF
increased significantly at 1 h myocardial ischaemia,
reached a peak level that was seven times that of
sham-ligated control after 3 h ischaemia, and de-
creased after 4 h ischaemia but remained significantly
higher compared with sham-ligated controls. The
level of serum TNF in the coronary reperfusion group
without BN 50739 pretreatment exceeded those in
the ischaemic groups, which was eleven times that of
sham-ligated controls. But in the groups pretreated
with BN 50739 before ischaemia and reperfusion the
TNF level decreased significantly compared with
vehicle controls after the same time period of
ischaemia and reperfusion. Serum TNF was detected
in five of nine (55.6%) rats in the sham-ligated group,
but was detected in all but two rats subjected to
coronary artery ligation or reperfusion; in two of the
nine rats pretreated with BN 50739 and subjected to
3 h coronary ligation TNF was not detected. The
differences in the percentage of animals showing
detectable serum TNF between sham-ligated and the
coronary artery ligated groups without BN 50739
pretreatment or both reperfused groups were signifi-
cant (p < 0.05). However, the difference between the
sham-ligated group and the 3 h ligated group
pretreated with BN 50739 was not significant.
Effect ofBN50739 on infarct size: As shown in Table
3, the infarct size significantly decreased in both
the 3 h ischaemia group and the 4 h reperfusion
group pretreated with BN 50739 compared with the
respective vehicle controls. The weights of left and
right ventricles in all groups were not significantly
different.
Linear correlation analysis showed that the corre-
lation coefficients between blood PAF level and
infarct size for Groups 2 and 3 (n 18), and Groups
7 and 8 (n= 18) were 0.502 (p< 0.05) and 0.614
(p< 0.01), respectively. Between serum TNF and
infarct size correlation coefficients for Groups 2 and
3 (n 18), and Groups 7 and 8 (n 18) were 0.479
(p < 0.05) and 0.608 (p < 0.01), respectively. Correla-
tion coefficients between the levels of PAF and TNF
were 0.469 (p < 0.05) for Groups 2 and 3 (n 18),
and 0.698 (p< 0.01) for Groups 7 and 8 (n 18).
Discussion
In this study it was found that the level of blood
PAF in the rats with coronary artery ligation from 1
to 4 h increased significantly, and increased further
in the rats subjected to 40 min coronary ligation
followed by a 4 h reperfusion, indicating that synthe-
sis and release of PAF may increase during acute
Table 3. Effects of BN 50739 on infarct size in rats subjected to
coronary artery ligation and reperfusion
Group n Treatment WV (mg) IS (mg) IS/WV (%)
2 9 BN 50739 902 + 170 220 + 4" 24.4 + 2.1"
3 8 Vehicle 872 + 169 258 + 7 29.6 + 4.0
7 9 BN 50739 906 + 146 95 + 7 10.5 + 4.5
8 9 Vehicle 882 + 144 251 + 14 28.5 + 9.5
IS infarct size; WV weight of left and right ventricles. "p < 0.05,
p < 0.01, compared with vehicle groups.
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myocardial ischaemia and reperfusion. A strong posi-
tive correlation existed between infarct size and
blood PAF level. BN 50739, a selective PAF receptor
antagonist, significantly reduced the infarct size in
the rats with 3 h coronary artery ligation and 4 h
reperfusion. This suggests that PAF may be an
important mediator involved in myocardial ischaemia
and reperfusion injury. There is evidence that plate-
lets, leukocytes, endothelial cells and cardio-
myocytes subjected to the stimuli of ischaemia and
hypoxia are very active in generating PAF. 8,9 The
mechanism by which PAF aggravates ischaemia and
reperfusion injury to the myocardium has not been
wholly clarified. It was reported that PAF, besides
inducing platelets located in the ischaemic
myocardial region to release vasoactive and
thrombogenic substances (thromboxane A2, etc.),
could increase the number of polymorphonuclear
leukocytes by its chemotaxic action in the ischaemic
region, activate these cells to release oxygen free
radicals and leukotrienes,1,1 and induce the dysfunc-
tion of endothelial cells (especially the coagulative
dysfunction).
11 These effects of PAF may contribute
to the myocardial damage during ischaemia and
reperfusion.
At a very low concentration (10-16 M) PAF can
release TNF from cultured monocytes/macro-
phages,
12 while cultured endothelial cells and neutro-
phils generate PAF and other cytokines when stimu-
lated by TNF. TNF enhances the procoagulant activ-
ity of endothelial cells, induces shock and tissue
injury, and increases vascular permeability and lethal
effects of PAF in animals. 13 Therefore, TNF might
aggravate ischaemic injury and extend myocardial
infarct size. In view of these facts, TNF might have a
close functional similarity to PAF in myocardial
ischaemia injury. The authors found that the percent-
age of animals exhibiting an increase in blood con-
centration of PAF and TNF increases simultaneously
during myocardial ischaemia and reperfusion, and
that infarct size was significantly correlated with both
PAF and TNF levels. This suggests that PAF and TNF
generated in a mutually stimulated way and had
synergic harmful effects on ischaemic and reperfused
myocardium. We also found that the maximal level
ofTNF appeared 1 h later than that of PAF, indicating
that PAF might be released first in myocardial
ischaemia and then stimulate the generation of TNF,
and thus PAF might have a potential central role in
the interaction between PAF and TNF.
Interestingly, the levels of PAF and TNF after 4 h
reperfusion were higher than the maximal levels in
rats with myocardial ischaemia. One possible expla-
nation for the phenomenon is that larger amounts of
PAF and TNF, generated and accumulated in the
ischaemic region, were released into blood when
reperfusion started. Another possibility is that
PAF and TNF were synthesized and released
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during the reperfusion period. Pathophysiologically,
reperfusion injury may partially differ from ischaemic
injury in that a large number of inflammatory cells
(mainly polymorphonuclear leukocytes) infiltrate
and are trapped in the ischaemic area and then
adhere increasingly to endothelial cells during
reperfusion, resulting in a ’no reflow region’. The
correlations between infarct size and level of PAF or
TNF in the rats undergoing reperfusion were more
significant than in the rats undergoing ischaemia in
the present study, indicating that PAF and TNF may
contribute more to injury resulting during myocardial
reperfusion than that during ischaemia. The effect of
BN 50739 in reducing infarct size observed in the
present study indicates that BN 50739 may behave
as a cellular protective agent and prevent more
cardiomyocytes from irreversible ischaemia and
reperfusion injury. BN 50739 may exert its effect by
closely binding itself to the PAF receptor in the target
organs, since the level of blood PAF in the rats with
ischaemia or reperfusion pretreated with BN 50739
did not differ from that in the vehicle controls, but
the reduction in the infarct size was remarkable. It is
worth emphasizing that the level of serum TNF in the
rats with ischaemia and reperfusion pretreated with
BN 50739 decreased significantly when compared
with vehicle controls in this study, supporting further
that a positive feedback of interaction between PAF
and TNF existed and that a part of the biological
activity of PAF was mediated via TNF.
In conclusion, the present results suggest that both
PAF and TNF are important mediators involved in
myocardial ischaemia and reperfusion injury. They
prime each other’s generation and release and exert
synergic harmful effects on the ischaemic and
reperfused myocardium. The PAF receptor antago-
nist, BN 50739, may inhibit the positive feedback of
PAF in releasing TNF, protect cardiomyocytes against
the injury, and thus decrease infarct size when ad-
ministered before ischaemia and reperfusion. Further
studies may be needed to define whether the com-
bination of PAF antagonist with TNF antibodies
could produce more benefit in the prevention and
treatment of myocardial ischaemia and reperfusion
injury.
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